Beam Therapeutics

Nov 08, 2021

•

Sep 30, 2021

Beam Therapeutics Q3 2021 Earnings Report

Reported business and pipeline updates and financial results for the third quarter of 2021.

Key Takeaways

Beam Therapeutics announced the FDA clearance of its IND application for BEAM-101, initiated IND-enabling studies for BEAM-102, and continued progress on BEAM-201. They also executed a non-exclusive option and license agreement with Sana Biotechnology for Cas12b.

FDA cleared IND application for BEAM-101 for sickle cell disease treatment.

Initiated IND-enabling studies for BEAM-102 for sickle cell disease treatment.

Continued progress on BEAM-201 for T-cell acute lymphoblastic leukemia treatment.

Executed non-exclusive option and license agreement with Sana Biotechnology for Cas12b.

Previous year: -$0.69

-39.1%